Hyaluronidase


Generic Medicine Info
Indications and Dosage
Parenteral
Enhancement of absorption and dispersion of injected drugs
Adult: As 1,500 units/mL solution: 1,500 units directly added into the solution to be injected (for SC or IM inj). As 150 units/mL or 200 units/mL solution: 50-300 units (usual dose: 150 units) added into the inj solution.

Parenteral
Aid in the diffusion of local anaesthetics
Adult: As 1,500 units/mL solution: 1,500 units mixed with local anaesthetic solution. In ophthalmology: 15 units/mL mixed with ophthalmic local anaesthetic solution.

Parenteral
Adjunct in hypodermoclysis
Adult: As 1,500 units/mL solution: 1,500 units (dissolved in 1 mL of water for inj or NaCl 0.9% solution) via SC inj into the site prior to infusion setup, or via inj into the tubing of the infusion set (approx 2 cm back from the needle) at the start of infusion. Dose is sufficient for administration of 500-1,000 mL infusion fluid. As 150 units/mL or 200 units/mL solution: 150 units or 200 units respectively, via SC inj before the start of SC fluid administration to facilitate absorption of ≥1,000 mL solution, or via addition into small volumes (up to 200 mL) of SC replacement fluid. Dosage, rate of inj and type of solution used must be individualised. Rate and volume of administration should not exceed those used for IV infusion.

Parenteral
Aid in the dispersal of extravasated fluids or blood
Adult: As 1,500 units/mL solution: 1,500 units (dissolved in 1 mL of water for inj or NaCl 0.9% solution) via local infiltration into the affected area as soon as possible after extravasation.

Subcutaneous
Adjunct in subcutaneous urography for improving resorption of radiopaque agents
Adult: As 150 units/mL or 200 units/mL solution: 75 units over each scapula, followed by inj of the contrast medium at the same sites. Patient must be in a prone position during the inj.
Child: Infants and children Same as adult dose.
Incompatibility
Incompatible with furosemide, phenytoin, benzodiazepines, heparin and epinephrine.
Contraindications
Hypersensitivity. Reduction of swelling of bites or stings. Inj into or around acutely inflamed area, or site with infection or malignancy. Direct application into the cornea; IV administration. Enhancement of absorption and dispersion of dopamine and/or α-agonist drugs; for anaesthetic procedures in unexplained premature labour.
Special Precautions
Patient with a known history of bee sting allergy. Children and elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Rarely, allergic reactions (e.g. urticaria, angioedema).
Eye disorders: Periorbital oedema (in conjunction with local anaesthetics in ophthalmology).
General disorders and administration site conditions: Local inj site reactions (e.g. pain, erythema); oedema (in association with hypodermoclysis).
IM/Intradermal/Intraocular/Parenteral/SC: C
Monitoring Parameters
Consider performing skin tests before administration. Document and monitor the extravasation site (when used in extravasation management).
Drug Interactions
May increase the vasoconstricting effect of α-agonist drugs. May enhance the toxic effects of local anaesthetics. Salicylates, cortisone, ACTH, estrogens and antihistamines may diminish the effects of hyaluronidase.
Action
Description:
Mechanism of Action: Hyaluronidase is an enzyme that acts as a dispersion agent by changing the connective tissue permeability through the hydrolysis of hyaluronic acid, a polysaccharide present in the intercellular matrix of connective tissue and certain specialised tissues. It temporarily reduces the viscosity of the cellular cement and promotes the dispersion of injected fluids or localised exudates, thereby enhancing their absorption.
Storage
Powder for solution for inj or infusion (1,500 units): Store below 25°C. Solution for inj (150 units/mL): Store between 2-8°C. Do not freeze. Solution for inj (200 units/mL): Store between 2-8°C. Do not freeze. Protect from light.
MIMS Class
Other Therapeutic Products
References
Amphadase Injection (Amphastar Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 01/08/2023.

Anon. Hyaluronidase. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/02/2024.

Artex Ltd. Hyalase Powder for Injection data sheet 19 February 2015. Medsafe. http://www.medsafe.govt.nz. Accessed 01/08/2023.

Buckingham R (ed). Hyaluronidase. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/02/2024.

Hyalase 1,500 I.U. Powder for Solution for Injection/Infusion (Wockhardt UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 01/08/2023.

Hyaluronidase Injection, Solution (HF Acquisition Co LLC, DBA HealthFirst). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 01/08/2023.

Hylenex Recombinant Injection, Solution (A-S Medication Solutions). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 01/02/2024.

Joint Formulary Committee. Hyaluronidase. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2023.

Vitrase Ovine Injection, Solution (Bausch & Lomb Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 01/02/2024.

Disclaimer: This information is independently developed by MIMS based on Hyaluronidase from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
  • Hyalase
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in